Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy
Hélène A. Emsellem(California Center for Sleep Disorders), Yves Dauvilliers(Inserm), Lawrence P. Carter(Jazz Pharmaceuticals (United States)), Giuseppe Plazzi(Istituto delle Scienze Neurologiche di Bologna), Diane Menno(Jazz Pharmaceuticals (United States)), Dan Chen(Wuhan University of Technology), Lawrence Lee(National Centre for Infectious Diseases), Colin M. Shapiro(University of Toronto), Kathleen F. Villa(Jazz Pharmaceuticals (United States)), Jed Black(Jazz Pharmaceuticals (United States)), Geert Mayer, Michael J. Thorpy(Montefiore Medical Center), Gert Jan Lammers(Leiden University Medical Center)
Cited by 192
Related Papers
National Sleep Foundation's sleep quality recommendations: first report
|Sleep Health|2016|1.3k
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
|Brain|2019|1.1k
Origins of the <i>E. coli</i> Strain Causing an Outbreak of Hemolytic–Uremic Syndrome in Germany
|New England Journal of Medicine|2011|833
Narcolepsy with cataplexy
|The Lancet|2007|716
Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment
|Nature Reviews Neurology|2019|634